我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Biohaven
相关临床试验
33
16 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
16
48.5%
Available
1
3.0%
已完成
10
30.3%
No Longer Available
2
6.1%
招募中
3
9.1%
终止
暂无批准数据
• Baird maintains an Outperform rating for Biohaven, encouraged by positive body composition changes observed in a Phase 3 SMA trial, signaling potential in the upcoming Phase 2 obesity trial. • Biohaven's management expresses strong optimism for their degrader platform, anticipating key results soon, which contributes to the positive outlook despite the recent Phase 3 SMA trial failure. • Despite a setback in the Phase 3 trial of taldefgrobep for spinal muscular atrophy (SMA), analysts remain confident in Biohaven's broader R&D portfolio, particularly its obesity program.
